11.43
-0.07(-0.61%)
Currency In USD
Previous Close | 11.5 |
Open | 11.5 |
Day High | 12.42 |
Day Low | 11.43 |
52-Week High | 1,248 |
52-Week Low | 10.83 |
Volume | 562,000 |
Average Volume | 1.65M |
Market Cap | 63.9M |
PE | 0 |
EPS | -8,039 |
Moving Average 50 Days | 28.32 |
Moving Average 200 Days | 114.15 |
Change | -0.07 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of February 14, 2025 at a share price of $11.43. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.04 as of February 14, 2025 at a share price of $11.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
GlobeNewswire Inc.
Feb 07, 2025 1:30 PM GMT
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities TNX-102 SL fibromyalgia FDA PDUFA goal date is Augu
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases
GlobeNewswire Inc.
Feb 06, 2025 1:00 PM GMT
Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 3
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
GlobeNewswire Inc.
Feb 05, 2025 12:00 PM GMT
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Leder